242 related articles for article (PubMed ID: 9114434)
1. Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.
el-akawi Z; Zdanowicz J; Creaven PJ; Abu-hadid M; Perez R; Pendyala L
Oncol Res; 1996; 8(10-11):415-23. PubMed ID: 9114434
[TBL] [Abstract][Full Text] [Related]
2. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells.
el-akawi Z; Abu-hadid M; Perez R; Glavy J; Zdanowicz J; Creaven PJ; Pendyala L
Cancer Lett; 1996 Jul; 105(1):5-14. PubMed ID: 8689632
[TBL] [Abstract][Full Text] [Related]
3. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
Yao KS; Godwin AK; Johnson SW; Ozols RF; O'Dwyer PJ; Hamilton TC
Cancer Res; 1995 Oct; 55(19):4367-74. PubMed ID: 7671249
[TBL] [Abstract][Full Text] [Related]
4. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
[TBL] [Abstract][Full Text] [Related]
5. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
7. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program.
Tew KD; Monks A; Barone L; Rosser D; Akerman G; Montali JA; Wheatley JB; Schmidt DE
Mol Pharmacol; 1996 Jul; 50(1):149-59. PubMed ID: 8700107
[TBL] [Abstract][Full Text] [Related]
8. Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance.
Kurokawa H; Ishida T; Nishio K; Arioka H; Sata M; Fukumoto H; Miura M; Saijo N
Biochem Biophys Res Commun; 1995 Nov; 216(1):258-64. PubMed ID: 7488097
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T
Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239
[TBL] [Abstract][Full Text] [Related]
10. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional up-regulation of gamma-glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells.
Mulcahy RT; Untawale S; Gipp JJ
Mol Pharmacol; 1994 Nov; 46(5):909-14. PubMed ID: 7969079
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract][Full Text] [Related]
13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of cyanohydroxybutene on glutathione synthesis in liver and pancreas of male rats.
Davis MA; Wallig MA; Eaton D; Borroz KI; Jeffery EH
Toxicol Appl Pharmacol; 1993 Dec; 123(2):257-64. PubMed ID: 7902618
[TBL] [Abstract][Full Text] [Related]
15. Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.
Bailey HH; Gipp JJ; Ripple M; Wilding G; Mulcahy RT
Cancer Res; 1992 Sep; 52(18):5115-8. PubMed ID: 1355406
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of pulmonary gamma-glutamylcysteine synthetase heavy subunit in rats exposed to cadmium aerosols.
Shukla GS; Chiu J; Hart BA
Toxicol Appl Pharmacol; 2000 Mar; 163(3):249-59. PubMed ID: 10702364
[TBL] [Abstract][Full Text] [Related]
17. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
18. gamma-Glutamyl transpeptidase (gamma-GT) and maintenance of thiol pools in tumor cells resistant to alkylating agents.
Ahmad S; Okine L; Wood R; Aljian J; Vistica DT
J Cell Physiol; 1987 May; 131(2):240-6. PubMed ID: 2884224
[TBL] [Abstract][Full Text] [Related]
19. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
